DEA Telehealth Prescribing Rules 2026: A PMHNP Deadline Guide

If you prescribe stimulants, benzodiazepines, or other controlled medications to patients you have only ever seen on video, this is the most important compliance date on your calendar. The rules below are federal. Your state prescriptive authority and your state telehealth law apply on top of them, and either can be stricter.

What a PMHNP Can Prescribe by Telehealth Today

The fourth temporary rule was published on December 31, 2025 and states that it "is effective January 1, 2026 through December 31, 2026." It covers every controlled schedule a PMHNP is likely to use.

The Four Conditions in the Temporary Rule

The regulation authorizes telemedicine prescribing without an in-person evaluation only when all of these are true:

1. The prescription is issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice.
2. The visit takes place over an interactive telecommunications system as Medicare defines it. That means audio and video. Audio-only is allowed only when the patient is at home and cannot use, or does not consent to, video.
3. Your DEA registration authorizes you to prescribe that class of controlled substance.
4. The prescription meets every other requirement of the DEA prescribing regulations in 21 CFR part 1306.

Nothing in the rule overrides state law. If your state requires a collaborating physician for Schedule II prescribing, or limits what a nurse practitioner may prescribe, that limit still applies. Our practice authority guide covers the state side.

What Happens on January 1, 2027

There are three possible outcomes, and as of October 5, 2026 nobody outside the government knows which one will happen.

A final special registration rule takes over. The DEA proposed a special registration framework in January 2025. The final version was received by the White House regulatory review office on August 25, 2026, and the government's own regulatory agenda lists November 2026 as the target for final action. The text is not public. A fifth extension is published. No further extension appears in the Federal Register or on the pending review list today. The 2024 extension was published in mid November and the 2025 extension on the last day of the year, so the absence of one in October does not settle the question. The flexibility lapses. If neither of those happens, starting a controlled substance by telemedicine would again require an in-person medical evaluation first, unless a standing exception applies. Those exceptions include buprenorphine for opioid use disorder, VA practitioners treating VA patients whom another VA practitioner has evaluated in person, and the categories written into the Ryan Haight Act itself, such as a patient who is physically located in, and being treated by, a DEA-registered hospital or clinic.

One point removes a great deal of risk. The DEA states that once a practitioner has conducted at least one in-person medical evaluation of a patient, the remote prescribing restrictions "no longer apply to that specific practitioner-patient relationship." A single in-person visit protects that relationship no matter which outcome arrives.

What the 2025 Proposal Would Have Required

The final rule may differ, but the proposal shows what the agency was considering. For Schedule II prescribing under a special registration, the proposal would have required:

• Board certification for mid-level practitioners, which is the DEA's category for nurse practitioners
• The prescriber to be located in the same state as the patient
• Telemedicine Schedule II prescriptions to make up less than 50 percent of the prescriber's monthly Schedule II prescriptions

Whether any of these survive is unknown. They are worth knowing because a practice built entirely on multi-state video visits for ADHD would be the most exposed if they do.

Medicare Runs on a Different Clock

Do not confuse the DEA deadline with Medicare's. The Consolidated Appropriations Act, 2026, signed February 3, 2026, extended Medicare telehealth flexibilities through December 31, 2027. CMS guidance says that through that date beneficiaries can receive Medicare telehealth services anywhere in the United States. The in-person visit requirement for tele-mental-health starts January 1, 2028. Patients who begin mental health services on or before December 31, 2027 will then need one in-person visit every 12 months.

For behavioral health specifically, the removal of geographic limits and the home as an eligible site are already permanent.

A Checklist to Finish Before December 31

1. Run a report of every patient on a controlled medication. Mark the ones you have never evaluated in person.
2. Offer in-person evaluations where you can. One visit removes the federal restriction for that patient for as long as you treat them.
3. Plan for patients you cannot see in person. Identify local prescribers or clinics for referral, and document the plan in the chart.
4. Confirm your registrations. Check that your DEA registration and state controlled substance authority cover every state and schedule you prescribe in. Our multi-state DEA guide walks through the process.
5. Ask your employer for its written plan. A telehealth company that prescribes controlled substances should be able to tell you what it will do on January 1 under each outcome. If it cannot, treat that as information about the employer.
6. Watch the Federal Register in November and December. That is where a final rule or an extension will appear first.

Registration and Training Facts Worth Rechecking

• The DEA practitioner registration fee is $888 for a three-year registration. The DEA sets the fee, and we found no proposal to change it in 2025 or 2026.
• The MATE Act training is a one-time requirement of 8 hours on substance use disorders. The DEA says the attestation "will not be a part of future registration renewals."
• A law signed December 1, 2025 added the American Psychiatric Nurses Association to the list of named training providers, so APNA training counts.

Where This Leaves Your Job Search

Telehealth roles are not going away, but the safest ones are built to survive any of the three outcomes. Look for employers with physical clinic access, a clear in-person evaluation pathway, and prescribing policies that leave clinical judgment with the clinician. You can compare current telehealth PMHNP jobs and remote PMHNP jobs with those questions in mind.

Sources

• DEA and HHS, Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities, 90 FR 61301 (December 31, 2025): https://www.govinfo.gov/content/pkg/FR-2025-12-31/html/2025-24123.htm
• DEA, Expansion of Buprenorphine Treatment via Telemedicine Encounter, 90 FR 6504 (January 17, 2025): https://www.federalregister.gov/documents/2025/01/17/2025-01049/expansion-of-buprenorphine-treatment-via-telemedicine-encounter
• DEA, Special Registrations for Telemedicine (proposed rule), 90 FR 6541 (January 17, 2025): https://www.govinfo.gov/content/pkg/FR-2025-01-17/html/2025-01099.htm
• Office of Information and Regulatory Affairs, Unified Agenda entry for RIN 1117-AB40: https://www.reginfo.gov/public/do/eAgendaViewRule?pubId=202510&RIN=1117-AB40
• CMS, Telehealth FAQ, updated February 26, 2026: https://www.cms.gov/files/document/telehealth-faq-updated-02-26-2026.pdf
• DEA Diversion Control Division, registration questions and answers: https://www.deadiversion.usdoj.gov/faq/registration-faq.html

This article summarizes federal rules as published on October 5, 2026. It is not legal advice. Confirm the current rule and your state requirements before changing how you prescribe.